Two Doses of Dexmedetomidine as Adjuvent to Bupivacaine in Tap Block (Dexmed/tap)

Assiut University

Status: Not yet enrolling

Conditions: Post Operative Pain

Treatments: Drug: Dexmedetomidine as adjuvent to bupvacaine in tap block

Study type: Interventional

Funder types: Other

Identifiers

NCT06624319

04-2024-200895

Details and patient eligibility

About

The aim of this study to determine the optimal dose of dexmedetomidine as an adjuvant to bupivacaine in U.S guided TAP block for preemptive analgesia In patients undergoing lower abdominal cancer surgeries.

Full description

The transversus abdominis plane (TAP) involves innervations of the anterolateral abdominal wall derived from T6-L1. The block can be given either by anatomical landmark technique or by using an ultrasound probe. The local anesthetic is deposited in a plane between internal oblique and transversus abdominis muscle. It provides adequate postoperative analgesia following various abdominal surgeries.Dexmedetomidine is an alpha-2 agonist that has been approved as a venous sedative and an adjuvant for pain relief .In previous studies, the addition of dexmedetomidine to bupivacaine in the TAP block has prolonged the effect of this block . So far, the optimal dose of dexmedetomidine for the TAP block has not been determined.

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age from 18 to 65 years old
• lower abdominal cancer surgery

Exclusion criteria

• patient refusal
• the local anesthetic allergy
• coagulopathy
• local infection at the procedure site
• psychic patients
• patient on chronic opioid use

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

50 participants in 2 patient groups

tap block with 0.5 μg/kg dexmedetomidine

Active Comparator group

Description:

will receive pre-emptive ultrasound-guided tap block with 0.5 μg/kg dexmedetomidine in 20 ml volume added to 20 mL of 0.25% bupivacaine (40 ml in total) 20 ml will be applied on each side of the abdominal wall after induction of GA.

Treatment:

Drug: Dexmedetomidine as adjuvent to bupvacaine in tap block

tap block with 1.5 μg/kg dexmedetomidine

Active Comparator group

Description:

will receive pre-emptive ultrasound-guided tap block with 1.5 μg/kg dexmedetomidine in 20 ml volume added to 20 mL of 0.25% bupivacaine (40 ml in total) 20 ml will be applied on each side of the abdominal wall after induction of GA.

Treatment:

Drug: Dexmedetomidine as adjuvent to bupvacaine in tap block